CLDX
Celldex Therapeutics (NASDAQ: CLDX) reported topline results from Celldex Therapeutics's Phase 2 study of...
Article Summary
SELL- Celldex Therapeutics (NASDAQ: CLDX) reported topline results from Celldex Therapeutics's Phase 2 study of barzolvolimab delivered subcutaneously in prurigo nodularis, a chronic skin disease that causes hard, intensely itchy lumps/nodules to form on the skin.
- The primary endpoint of the study, proportion of patients who achieve four points or greater improvement in WI-NRS (Worst Itch Numeric Rating Scale) from baseline to Week 12, was not met, and key secondary endpoints were not met.
- Profound mast cell depletion as evidenced by significant reduction in serum tryptase was observed and did not result in improvement in itch or skin lesions in patients with PN compared to placebo, indicating mast cells may not be a key pathogenic driver of symptoms in PN.
- Based on these results, Celldex is discontinuing the Phase 2 trial, with Celldex Therapeutics remaining focused on driving mast cell category creation for allergic, inflammatory, and autoimmune diseases.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | -88.5% | 25% | 0.0 ptsDeclining (-88.5%) - NOT a growth stock |
| EPS Growth Next 5Y ? | 5.0% | 25% | 20.0 ptsWeak (5.0%) - Low expectations |
| Target Price Upside ? | 60.6% | 20% | 100.0 ptsMassive Upside (60.6%) - Target: $57.27 vs Current: $35.66 |
| Gross Margin % ? | -288.8% | 15% | 10.0 ptsRazor-Thin (-288.8%) - Weak pricing power |
| Drawdown from 52-Wk High ? | -11.5% | 15% | 40.0 ptsMild Pullback (-11.5%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About CLDX
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.
- The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
- It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation.
- Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.